Loss of RESponse to Ustekinumab Treated by Dose Escalation

NCT04245215 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

108

Enrollment

OTHER

Sponsor class

Conditions

Crohn Disease

Interventions

DRUG: Ustekinumab

Sponsor

Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW

Collaborators

[object Object]